REFERENCES
- Mathers WD. Why the eye becomes dry: a cornea and lacrimal gland feedback model. CLAO J. 2000; 26(3)159–165
- Roberts DK. Keratoconjunctivitis sicca. J. Am. Optom. Assoc. 1991; 62(3)187–199
- Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J. 1995; 21(4)221–232
- Pflugfelder SC. DA Sullivan, DA Dartt, MA MenerayTear fluid influence on the ocular surface. Lacrimal Gland, Tear Film and Dry Eye Syndromes 2, . Plenum Press, New York, NY 1998; 611–617
- Ohashi Y, Motokura M, Kinoshita Y, et al. Presence of epidermal growth factor in human tears. Invest. Ophthalmol. Vis. Sci. 1989; 30(8)1879–1882
- Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998; 17(6)584–589
- Ohashi Y, Ishida R, Kojima T, et al. Abnormal protein profiles in tears with dry eye syndrome. Am. J. Ophthalmol. 2003; 136(2)291–299
- Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren's syndrome keratoconjunctivitis sicca. Curr. Eye Res. 1999; 19(3)201–211
- Haigler HT, Carpenter G. Production and characterization of antibody blocking epidermal growth factor:receptor interactions. Biochim. Biophys. Acta. 1980; 598(2)314–325
- Lohmann CP, Goepferich A, Koelwel C, inventors, Lohmann CP, assignee. Insert for the treatment of dry eye. International Patent WO 03/005941 A2. July 12, 2002
- Wilson CG, Zhu YP, Frier M, Rao LS, Gilchrist P, Perkins AC. Ocular contact time of a carbomer gel (GelTears) in humans. Br. J. Ophthalmol. 1998; 82(10)1131–1134
- Bawa R. AK MitraOcular inserts. Ophthalmic Drug Delivery Systems, . Dekker, New York, NY 1993; 223–259
- Shell JW. Ophthalmic drug delivery systems. Drug Dev. Res. 1985; 6(3)245–261
- Martinsen A, Storroe I, Skjaak-Braek G. Alginate as immobilization material: III. Diffusional properties. Biotechnol. Bioeng. 1992; 39(2)186–194
- Smidsrod O, Skjak-Braek G. Alginate as immobilization matrix for cells. Trends Biotechnol. 1990; 8: 71–78
- Gombotz WR, Wee S. Protein release from alginate matrices. Adv. Drug Deliv. Rev. 1998; 31(3)267–285
- Fuchs-Koelwel B, Koelwel C, Gopferich A, Gabler B, Wiegrebe E, Lohmann CP. Tolerance of a new calcium-alginate-insert for controlled medication therapy of the eye. Ophthalmologe. 2004; 101(5)496–499
- DiBiase MD, Rhodes CT. The design of analytical methods for use in topical epidermal growth factor product development. J. Pharm. Pharmacol. 1991; 43(8)553–558
- Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev. Ther. Drug Carrier Syst. 1993; 10(4)307–377
- Norn MS. Lissamine green: vital staining of cornea and conjunctiva. Acta Ophthalmol. (Copenh). 1973; 51(4)483–491
- Senderoff RI, Wootton SC, Boctor AM, et al. Aqueous stability of human epidermal growth factor 1–48. Pharm. Res. 1994; 11(12)1712–1720
- Zaks A. TJ Ahern, MC ManningProtein-water interactions: role in protein structure and stability. Stability of Protein Pharmaceuticals; Part A, . Plenum Press, New York, NY 1992; 249–271
- Clarke S, Stephenson RC, Lowenson JD. TJ Ahern, MC ManningLability of asparagine and aspartic acid residues in proteins and peptides. Spontaneous deamidation and isomerization reactions. Stability of Protein Pharmaceuticals, Part A, . Plenum Press, New York, NY 1992; 1–29
- Amsden B, Turner N. Diffusion characteristics of calcium alginate gels. Biotechnol. Bioeng. 1999; 65(5)605–610
- Draget KI, Smidsrod O, Skjak-Braek G. Alginates from algae. Biopolymers. 2002; 6: 215–244
- Klaassen-Broekema N. The diagnostic power of the tests for tear gland related keratoconjunctivitis sicca. Neth. J. Med. 1992; 40(3–4)113–116
- Lemp MA, Hamill JR, Jr. Factors affecting tear film breakup in normal eyes. Arch. Ophthalmol. 1973; 89(2)103–105
- Lemp MA. Breakup of the tear film. Int. Ophthalmol. Clin. 1973; 13(1)97–102